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Abstract
Objective: There is evidence that asthma is associated with an increase in psychiatric symptoms and mental 
disorders. This association can make it difficult to achieve asthma control. The purpose of this study was to 
determine whether the level of asthma control is associated with anxiety and depression. Methods: A cross-
sectional study involving 78 patients with confirmed moderate or severe asthma and under regular treatment at the 
Asthma Outpatient Clinic of the Federal University of São Paulo Hospital São Paulo, in the city of São Paulo, Brazil. 
The patients were divided into two groups by asthma control status, as assessed by the asthma control test, and 
were subsequently compared in terms of demographic, clinical, and spirometric data, as well as scores for asthma 
quality of life and hospital anxiety/depression. Results: The sample was predominantly female. Of the 78 patients, 
49 (63%) were classified as having uncontrolled asthma. The prevalence of anxiety and of anxiety+depression was 
significantly higher among patients with uncontrolled asthma than among those with controlled asthma (78% and 
100%; p = 0.04 and p = 0.02, respectively), whereas there were no differences between the two groups in terms of 
the prevalence of depression, spirometry results, or quality of life score. Conclusions: In this sample, the prevalence 
of anxiety symptoms was higher in the patients with uncontrolled asthma than in those with controlled asthma.In 
the evaluation of asthma patients, the negative impact of mood states ought to be taken into consideration when 
asthma control strategies are being outlined.
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Resumo
Objetivo: Existem evidências da associação entre asma e sintomas psiquiátricos e transtornos mentais. Essa 
associação pode resultar em dificuldades de se atingir o controle da asma. O objetivo deste estudo foi avaliar 
a associação de ansiedade e depressão com o controle da asma. Métodos: Estudo transversal com 78 pacientes 
asmáticos com diagnóstico confirmado de asma moderada a grave e regularmente tratados no Ambulatório de 
Asma do Hospital São Paulo da Universidade Federal de São Paulo, São Paulo (SP).Os pacientes foram divididos 
em dois grupos em relação ao status de controle de asma, determinado através do teste de controle da asma, e, 
posteriormente, comparados em termos de dados demográficos, clínicos e espirométricos, escore do questionário 
de qualidade de vida para asma e escore da escala hospitalar de ansiedade e depressão. Resultados: A maioria era 
do sexo feminino. Dos 78 pacientes, 49 (63%) foram classificados como tendo asma não controlada. A prevalência 
de ansiedade e do binômio ansiedade/depressão foi significantemente maior entre os pacientes não controlados do 
que nos controlados (78% e 100%; p = 0,04 e p = 0,02, respectivamente), enquanto nem prevalência de depressão, 
nem os dados espirométricos ou de qualidade de vida diferiram entre os grupos. Conclusões: Nesta amostra, os 
pacientes com asma não controlada apresentaram uma maior prevalência de sintomas de ansiedade que aqueles 
com asma controlada. Na avaliação de pacientes asmáticos, deve-se considerar o impacto negativo dos distúrbios 
de humor nas estratégias de controle da asma.
Descritores: Asma; Ansiedade; Depressão; Estudos transversais.
*Study carried out in the Universidade Federal de São Paulo/Escola Paulista de Medicina – UNIFESP/EPM, Federal University of 
São Paulo/Paulista School of Medicine – São Paulo, Brazil.
Correspondence to: Ana Luisa Godoy Fernandes. Disciplina de Pneumologia, Rua Botucatu, 740, 3° andar, CEP 04023-004, São Paulo, 
SP, Brasil.
Tel 55 11 5549-1830. Fax: 55 11 5904-2897. E-mail: analuisa@pneumo.epm.br
Financial support: None.
Submitted: 11 March 2010. Accepted, after review: 1 September 2010.
**A versão completa em português deste artigo está disponível em www.jornaldepneumologia.com.br
Original Article
14 Vieira AA, Santoro IL, Dracoulakis S, Caetano LB, Fernandes ALG
J Bras Pneumol. 2011;37(1):13-18
education and pharmacological therapy, in 
accordance with the 2006 GINA guidelines.(1) The 
study protocol was approved by the local research 
ethics committee (ruling no. 1375/06), and all 
participants gave written informed consent.
The inclusion criteria were having a confirmed 
diagnosis of moderate or severe asthma,(1) being 
≥ 18 years of age, and having been under 
outpatient follow-up treatment for more than 
six months.(15)
We selected 82 patients, 4 of whom were 
excluded: 2 because they declined to participate; 
and 2 because there were missing data. Therefore, 
78 patients completed the study.
We collected demographic data (age and 
gender), clinical data (maintenance medication 
in use for over a month), and spirometric data 
(FEV1, FVC, and FEV1/FVC ratio prior to and after 
the use of an inhaled short-acting β2 agonist). 
Spirometry was performed in accordance with 
the Brazilian Thoracic Society guidelines.(16) 
The patients also completed the following 
instruments: the ACT; the asthma quality of life 
questionnaire (ACQL); and the hospital anxiety 
and depression scale (HADS).
The level of asthma control was assessed with 
the ACT,(4) a self-administered questionnaire that 
is useful for quantifying asthma control and has 
been validated for such use. This questionnaire was 
developed in order to assess asthma control, and 
it has shown strong evaluative and discriminative 
properties.(4) It consists of 5 questions, related to the 
four weeks preceding the evaluation, addressing 
multiple dimensions of control, including 
episodes of breathlessness, nocturnal awakenings, 
limitations in activities of daily living, self-rating 
of asthma control, and need for relief medication. 
Each question is scored on a 6-point scale—from 
0 (good control) to 5 (poor control)—and the total 
score therefore ranges from 5 to 25. A score ≥ 20 
on the ACT is defined as controlled asthma.
Asthma severity was stratified into five levels 
in accordance with 2006 GINA guidelines(1): 
level 1, use of relief medications only; level 2, 
use of low doses of inhaled glucocorticosteroids 
(200-400 µg/day of budesonide); level 3: use of 
medium doses of inhaled glucocorticosteroids 
(400-800 µg/day of budesonide); level 4, use of 
inhaled glucocorticosteroids and a long-acting 
inhaled β2 agonist or montelukast/theophylline; 
and level 5, use of high doses of inhaled 
glucocorticosteroids plus a long-acting inhaled 
β2 agonist plus a third medication or an oral 
corticosteroid.
Introduction
Worldwide, asthma is one of the most 
common chronic diseases. The concept of 
asthma control was clearly outlined in the most 
recent revision of the Global Initiative for Asthma 
(GINA) guidelines. This concept encompasses 
asthma severity, asthma education, and 
management of the pharmacological treatment 
based on a step-up or step-down approach. 
Access to effective treatment allows asthma to 
be well controlled in most patients.(1,2) When 
uncontrolled, asthma can severely limit activities 
of daily living and can be even fatal.(1) Although 
impressive efforts have been made in order 
to improve asthma care over the last decade, 
asthma continues to be poorly controlled in a 
considerable number of patients.(1-3)
The asthma control test (ACT) is one of the 
tools that have been developed to quantify 
asthma control status. The ACT was designed to 
assess the multidimensional nature of asthma.(4) 
Many factors contribute to the lack of adequate 
control. One such factor, psychiatric disorders, 
has been studied as a modulator of uncontrolled 
asthma.(5-8)
Psychiatric disorders, mostly anxiety and 
depression, have been associated with asthma.(9-13) 
Asthma patients and patients with anxiety both 
exhibit a defensive behavior; the former, because 
of their repressive style of coping, might have an 
impaired ability to perceive asthma symptoms, a 
necessary prerequisite for following a personal 
asthma action plan, and the latter might have 
a heightened perception of their symptoms.(6,14) 
Therefore, the presence of anxiety or depression 
could affect the results of a self-administered 
multidimensional questionnaire such as the 
ACT.
Because of the abovementioned considerations, 
the objective of the present study was to determine 
whether asthma control status, as assessed by the 
ACT, is associated with anxiety and depression in 
patients under regular treatment for moderate or 
severe asthma.
Methods
This was a cross-sectional study conducted 
at the Asthma Outpatient Clinic of the Federal 
University of São Paulo Hospital São Paulo, a 
tertiary-care facility located in the city of São 
Paulo, Brazil. This clinic has a tailored program 
for asthma patients that consists of asthma 
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Results
As expected, females accounted for the 
vast majority (66%) of our sample, although 
there was no statistically significant difference 
between the genders in terms of asthma control 
status. Approximately 60% of the patients had 
uncontrolled asthma according to their ACT 
scores (< 20).
Uncontrolled asthma was significantly more 
common in the patients in whom asthma severity 
was classified as level 5 than in those in whom 
it was classified as level 2, 3, or 4, even when 
the last three were combined. The quality of life 
scores did not differ between the patients with 
controlled asthma and those with uncontrolled 
asthma (Table 1). In addition, the pre- and post-
bronchodilator spirometric values did not differ 
between the controlled asthma and uncontrolled 
asthma groups (Table 2).
We found that HADS scores diagnostic 
of anxiety, as well as those diagnostic of 
anxiety+depression, were significantly 
associated with uncontrolled asthma (Table 3). 
The prevalence of psychiatric disorders was 
significantly higher among the patients with 
uncontrolled asthma (Figure 1).
Figure 2 shows the distribution of the 
patients with psychiatric disorders (HADS 
scores diagnostic of anxiety, depression, or 
anxiety+depression), by ACT score.
The AQLQ is a disease-specific instrument for 
the determination of quality of life that has been 
validated for use in clinical trials. It contains 32 
questions comprising four domains: activity 
limitation, symptoms, emotional function, and 
environmental stimuli. Each item is scored on 
a 7-point scale, on which 1 indicates severe 
impairment, and 7 indicates no impairment.(17)
Anxiety and depression were assessed with 
the Portuguese-language version of the HADS, 
which has been extensively used in screening 
for psychiatric morbidity.(18) It consists of 14 
questions—7 for anxiety and 7 for depression, 
each scored from 0 to 3, the maximum score for 
either therefore being 21. Higher scores indicate 
more symptoms. A HADS anxiety score of ≥ 8 
was considered diagnostic of anxiety, whereas 
a HADS depression score of ≥ 9 was considered 
diagnostic of depression.(19,20)
Statistical analysis
The results are expressed as means and standard 
deviations or as medians and interquartile ranges. 
Categorical variables were compared using the 
chi-square test or Fisher’s exact test. Depending 
on the distribution, continuous variables were 
compared by the unpaired t-test or Mann-Whitney 
test. Values of p < 0.05 were considered statistically 
significant. Statistical analyses were performed 
using the statistical freeware R, version 2.10.1 
(R Development Core Team, 2009).
Table 1 - Characteristics, asthma control test scores, and asthma quality of life questionnaire scores, by asthma 
control status.
Variable Total  
(n = 78)
Asthma control status p
Controlled (n = 29) Uncontrolled (n = 49)
Age, yearsa 47.4 ± 13.1 48.2 ± 13.9 48.3 ± 13.4 0.36*
Female, % 66.2 30.8 69.2 0.10**
GINA, %
0.02d**
Level 2 8.4 60 40
Level 3 11.3 25 75
Level 4 64.8 50 50
Level 5 15.5 09 91
ACT scoreb 17.0 (5-25) 23.5 (20-25) 11.0 (5-19)
AQLQ scorec
Activity limitation 45.5 (25.8) 50.0 (18.2) 45.5 (29.5) 0.22
Symptoms 45.8 (66.7) 66.7 (66.7) 33.3 (66.6) 0.43
Environmental stimuli 50.0 (31.8) 55.6 (39.8) 45.5 (26.1) 0.11
Emotional function 55.7 (35.7) 39.3 (44.6) 35.7 (35.7) 0.90
Total 50.4 (30.0) 53.5 (32.1) 46.1 (29.1) 0.25
GINA: Global Initiative for Asthma; ACT: asthma control test; and AQLQ: asthma quality of life questionnaire. aValues 
expressed as mean ± SD. bValues expressed as median (range). cValues expressed as median (interquartile range). dLevel 5 
vs. levels 2, 3, and 4 combined. *Unpaired Student’s t-test. **Chi-square test.
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Table 2 - Spirometry results (% of predicted values), by asthma control status.a
Variable Total (n = 78) Asthma control status p
Controlled (n = 29) Controlled (n = 29)
Pre-BD
FEV1 72.4 ± 19.7 77.3 ± 9.8 68.9 ± 19.1 0.08
FVC 88.8 ± 17.2 92.1 ± 18.4 86.5 ± 16.2 0.18
FEV1/FVC 80.6 ± 13.0 82.5 ± 12.3 78.8 ± 13.7 0.25
Post-BD
FEV1 77.1 ± 19.9 78.9 ± 21.7 75.8 ± 18.6 0.52
FVC 93.1 ± 16.4 95.7 ± 17.6 91.4 ± 15.5 0.29
FEV1/FVC 84.4 ± 13.3 85.4 ± 12.2 83.7 ± 13.9 0.60
BD response, % 10.4 ± 11.8 9.7 ± 9.9 10.9 ± 12.2 0.66
BD: bronchodilator. aValues expressed as mean ± SD. *Unpaired Student’s t-test.
Table 3 - Frequency of anxiety symptoms and depressive symptoms, as determined by the hospital anxiety and 
depression scale, by asthma control status.
Symptoms of anxiety or 
depression
Total (n = 78) Asthma control status p*
Controlled (n = 29) Uncontrolled (n = 49)
None, n 37 20 17 0.002
Anxiety, n 23 5 18 0.040
Depression, n 9 4 5 0.720
Anxiety + depression, n 9 0 9 0.020
*Chi-square test or Fisher’s exact test.
Figure 1 - Proportion of patients with psychiatric 
disorders (anxiety, depression, or anxiety + depression), 
by asthma control status, as determined by the asthma 
control test.
Figure 2 - Presence of anxiety, depression, and anxiety 
+ depression, as determined by the hospital anxiety 
and depression scale, by asthma control test (ACT) 
score. ------ control level; ACT score ≥ 20: controlled 
asthma; ACT score < 20: uncontrolled asthma.
Discussion
Of the patients evaluated in this study, 53% 
had anxiety, depression, or anxiety+depression. 
This is in accordance with the findings of various 
studies showing that the prevalence of anxiety 
and depressive disorders is elevated among 
asthma patients.(9,21,22)
In our study, the overwhelming majority of 
the patients not only exhibited the anxiety profile 
but also had uncontrolled asthma. In addition, 
none of the patients with controlled asthma, 
according to the ACT, had anxiety+depression. 
It has been reported that there is a strong 
association between psychiatric disorders and 
uncontrolled asthma.(9,10,23) Might this association 
be two sides of the same coin? On the one hand, 
the higher prevalence of anxiety among patients 
with uncontrolled asthma might promote mood 
disorders, which in turn might increase symptom 
perception in such patients, thereby reducing 
their perception of asthma control.(9,14) On the 
other hand, the respiratory symptoms that are 
secondary to mood disorders might impede the 
evaluation of asthma control, because certain 
symptoms of anxiety (shortness of breath and 
rapid HR) and depression (insomnia and fatigue) 
could overlap with those of asthma. To avoid 
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of our study sample, they were proportionally 
distributed by asthma control status. Nor did 
anxiety and depression scores differ between 
the genders, although anxiety and insomnia 
have been reported to be more common among 
women with asthma than among men with 
asthma.(28) It is crucial to consider the differential 
impact of negative mood states when assessing 
asthma control and quality of life.(24)
The present study has the intrinsic limitations 
of a cross-sectional observational study. 
Therefore, it is impossible to determine whether 
anxiety was the cause or the consequence 
of uncontrolled asthma. Another potential 
limitation is the fact that, in order to avoid the 
bias of including undertreated patients, which 
would have increased the number of patients 
with uncontrolled asthma, we only included 
patients participating in a special education 
program, on an intention-to-treat basis.
In conclusion, the prevalence of anxiety 
was higher in the patients with uncontrolled 
asthma than in those with controlled asthma. It 
is noteworthy that, in the evaluation of asthma 
patients, the negative impact that mood states 
have on asthma control ought to be taken into 
consideration.
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